- Home
- GPCR vs IBRX Comparison
GPCR vs IBRX Comparison
Compare GPCR & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- IBRX
- Stock Information
- Founded
- GPCR 2016
- IBRX 2014
- Country
- GPCR United States
- IBRX United States
- Employees
- GPCR N/A
- IBRX N/A
- Industry
- GPCR
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GPCR
- IBRX Health Care
- Exchange
- GPCR Nasdaq
- IBRX Nasdaq
- Market Cap
- GPCR 1.6B
- IBRX 1.9B
- IPO Year
- GPCR 2023
- IBRX N/A
- Fundamental
- Price
- GPCR $23.77
- IBRX $3.42
- Analyst Decision
- GPCR Strong Buy
- IBRX Strong Buy
- Analyst Count
- GPCR 7
- IBRX 3
- Target Price
- GPCR $81.29
- IBRX $13.58
- AVG Volume (30 Days)
- GPCR 752.3K
- IBRX 6.0M
- Earning Date
- GPCR 03-07-2025
- IBRX 03-18-2025
- Dividend Yield
- GPCR N/A
- IBRX N/A
- EPS Growth
- GPCR N/A
- IBRX N/A
- EPS
- GPCR N/A
- IBRX N/A
- Revenue
- GPCR N/A
- IBRX $7,332,000.00
- Revenue This Year
- GPCR N/A
- IBRX $2,359.81
- Revenue Next Year
- GPCR N/A
- IBRX $808.10
- P/E Ratio
- GPCR N/A
- IBRX N/A
- Revenue Growth
- GPCR N/A
- IBRX 1218.71
- 52 Week Low
- GPCR $22.33
- IBRX $2.28
- 52 Week High
- GPCR $62.74
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- GPCR 37.89
- IBRX 52.26
- Support Level
- GPCR $22.33
- IBRX $3.35
- Resistance Level
- GPCR $25.17
- IBRX $4.27
- Average True Range (ATR)
- GPCR 1.73
- IBRX 0.31
- MACD
- GPCR -0.37
- IBRX 0.04
- Stochastic Oscillator
- GPCR 15.94
- IBRX 29.17
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.